肝细胞癌合并晚期肝功能不全患者的全身治疗
晚期肝细胞癌的全身治疗传统上限于Child-Pugh A级患者,西方指南推荐主要用于肝功能保留者。Child-Pugh B级患者临床常见但缺乏前瞻性证据和明确指导。本文讨论肝硬化临床病程对治疗资格的影响、改善肝功能的策略,总结Child-Pugh B级患者全身治疗文献,并提出临床处理流程。
要点
- 西方指南推荐全身治疗主要用于肝功能保留的肝细胞癌患者。
- Child-Pugh B级患者因缺乏前瞻性证据,尚无明确最佳管理指导。
- 本文提出针对肝细胞癌合并晚期肝功能不全患者的临床处理流程。
核心结论
- 基于现有信息,作者提出了一套在临床实践中系统处理肝细胞癌合并晚期肝功能不全患者的临床流程。
研究设计与样本
- 本文为近期进展综述,讨论肝硬化临床病程对现代全身治疗时代肝细胞癌治疗资格的影响,总结Child-Pugh B级患者全身治疗的现有文献。
主要发现
- 关键III期试验传统上仅纳入Child-Pugh A级患者,因为该人群中死亡更可能归因于肝细胞癌进展。
- Child-Pugh B级肝细胞癌患者在临床实践中常见,但由于前瞻性证据有限,其最佳管理尚无明确指导。
- 作者阐述了通过针对肝硬化相关和肿瘤相关因素来改善肝细胞癌患者肝功能的策略。
关键数值与推荐
- 西方指南推荐全身治疗主要用于肝功能保留的肝细胞癌患者。
- 关键III期试验传统上仅纳入Child-Pugh A级患者。
临床怎么用
- 作者提出了一套临床流程,用于在临床实践中系统处理肝细胞癌合并晚期肝功能不全的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients with advanced liver dysfunction, pivotal phase III trials traditionally limited inclusion to patients with Child-Pugh class A, where death is more likely to be attributed to HCC progression. Therefore, Western guidelines recommend the use of systemic therapies primarily in patients with preserved liver function. However, patients with HCC and Child-Pugh class B are commonly encountered in clinical practice, but due to limited prospective evidence, there is no clear guidance on their optimal management.In this recent advances article, we discuss how the clinical course of cirrhosis can affect eligibility to treatment in the modern era of systemic therapy for HCC, elaborate on strategies to improve liver function in HCC patients by targeting cirrhosis-related and tumour-related factors and summarise the current literature on systemic therapy in HCC patients with Child-Pugh class B. Based on this information, we finally propose a clinical algorithm on how to systematically approach patients with HCC and advanced liver dysfunction in clinical practice.
引用
- Pinter M, Fulgenzi CAM, Pinato DJ, et al. Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction. Gut. 2025. PMID: 40301119. doi:10.1136/gutjnl-2025-334928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。